President Donald Trump on Thursday announced a deal that could significantly expand access for millions of Americans to hugely popular obesity drugs by reducing the price to as little as $149 a month.

The Trump administration’s agreements with drugmakers Novo Nordisk and Eli Lilly would save consumers and the government considerable money on Wegovy, Zepbound and two obesity pills that are expected to win regulatory approval in the coming months.

The lowest price, of $149 a month, will be available only for the lowest doses of the pill form of the drugs. When those drugs reach the market, Medicare and Medicaid will pay that price, as will Americans using their own money to buy the pills directly from manufacturers.

Trump, top U.S. health officials and drug company executives at the White House outlined broader coverage of the injectable drugs for people on Medicare and Medicaid, the federal insurance programs for older people; many who have disabilities; and those with lower incomes. The deal also lowers the prices the government programs will pay.

Those measures are likely to expand access but still will stop far short of covering all of the millions of people with obesity under the federal programs.

Officials said that within the next few months, Americans would be able to use their own money to buy Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound — which are each taken as weekly injections — directly from manufacturers for an average of $350 a month, depending on the dose. The officials said they expected the average cost to fall to $245 over the next two years.

Starting around the middle of next year, Medicare and Medicaid’s costs for the injectable drugs will drop to $245 a month. That coverage will be for people who meet certain medical criteria, like having moderate or severe obesity. People can also have mild obesity accompanied by kidney disease, heart failure or uncontrolled high blood pressure. Or they can have a body mass index of 27 alongside prediabetes or established cardiovascular disease.

Copayments for eligible patients on Medicare will be no more than $50 a month. Patients on Medicaid already have little to no out-of-pocket costs.

“This is tremendous savings,” Trump said in the Oval Office event Thursday announcing the deal.

At the event, Trump referred to the medications as “the fat drug.” He mused as to whether his Cabinet members in the room were taking the drugs. (“Not yet,” quipped Commerce Secretary Howard Lutnick.

Nor does Dr. Mehmet Oz, who runs Medicare and Medicaid.) Trump did not say whether he had ever tried them.

Administration officials offered an extraordinary projection that the moves would help Americans collectively lose 135 million pounds by the midterm elections next year, without explaining how they arrived at that guesstimate.